Bimagrumab for sporadic inclusion body myositis – first line
NIHR HSRIC
Record ID 32016000420
English
Authors' objectives:
Sporadic inclusion body myositis is a rare disease that affects the muscles of older people. It causes weakness and can lead to difficulties standing and walking safely without falling. There is currently no treatment for this disease.
Bimagrumab is a new drug being developed for sporadic inclusion myositis. It is given straight into the blood stream through a drip once every 4 weeks. A study is currently running to see how well it works to improve patients' walking abilities and to see if it is safe to use.
If it is licensed for use in the UK, bimagrumab will be the first treatment available for people with sporadic inclusion body myositis.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/bimagrumab-for-sporadic-inclusion-body-myositis-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Antibodies, Blocking
- Antibodies, Monoclonal
- Myositis
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.